TPST
Income statement / Annual
Last year (2025), Tempest Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Tempest Therapeutics Inc's net income was -$26.26 M.
See Tempest Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$295.00 K |
$653.00 K |
| Cost of Revenue |
$0.00
|
$389.00 K
|
$0.00
|
$0.00
|
$0.00
|
$815.00 K
|
$0.00
|
$32.00 K
|
$28.00 K
|
$5.40 M
|
| Gross Profit |
$0.00
|
-$389.00 K
|
$0.00
|
$0.00
|
$0.00
|
-$815.00 K
|
-$1.05 M
|
-$32.00 K
|
$267.00 K
|
-$4.75 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0.91
|
-7.27
|
| Research and Development Expenses |
$12.61 M
|
$28.48 M
|
$17.50 M
|
$22.53 M
|
$17.17 M
|
$14.39 M
|
$27.84 M
|
$14.43 M
|
$14.53 M
|
$21.64 M
|
| General & Administrative Expenses |
$13.97 M
|
$13.55 M
|
$11.66 M
|
$12.11 M
|
$9.82 M
|
$0.00
|
$17.56 M
|
$8.69 M
|
$27.74 M
|
$49.22 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$16.50 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.97 M
|
$13.55 M
|
$11.66 M
|
$12.11 M
|
$9.82 M
|
$4.09 M
|
$16.50 M
|
$8.66 M
|
$5.93 M
|
$49.22 M
|
| Other Expenses |
$0.00
|
-$389.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$26.58 M
|
$41.64 M
|
$29.16 M
|
$34.64 M
|
$26.99 M
|
$18.48 M
|
$44.35 M
|
$23.08 M
|
$20.45 M
|
$70.86 M
|
| Cost And Expenses |
$26.58 M
|
$42.03 M
|
$29.16 M
|
$34.64 M
|
$26.99 M
|
$19.30 M
|
$45.40 M
|
$23.12 M
|
$20.48 M
|
$76.27 M
|
| Interest Income |
$520.00 K
|
$1.50 M
|
$1.12 M
|
$549.00 K
|
$1.28 K
|
$90.00 K
|
$264.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$207.00 K
|
$1.32 M
|
$1.45 M
|
$1.62 M
|
$1.28 M
|
$0.00
|
$0.00
|
$134.00 K
|
$0.00
|
$659.00 K
|
| Depreciation & Amortization |
$266.00 K
|
$389.00 K
|
$381.00 K
|
$638.00 K
|
$374.00 K
|
$815.00 K
|
$1.05 M
|
$32.00 K
|
$28.00 K
|
$2.24 M
|
| EBITDA |
-$25.79 M |
-$40.14 M |
-$27.66 M |
-$33.45 M |
-$26.65 M |
-$18.39 M |
-$43.52 M |
-$27.01 M |
-$84.27 M |
-$79.82 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-285.66
|
-122.24
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-69.43
|
-124.06
|
| Total Other Income/Expenses Net |
$313.00 K
|
$183.00 K
|
-$334.00 K
|
-$1.07 M
|
-$1.32 M
|
$90.00 K
|
$831.00 K
|
-$4.06 M
|
-$64.10 M
|
-$6.45 M
|
| Income Before Tax |
-$26.26 M
|
-$41.84 M
|
-$29.49 M
|
-$35.71 M
|
-$28.30 M
|
-$19.21 M
|
-$44.57 M
|
-$27.18 M
|
-$84.59 M
|
-$82.06 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-286.73
|
-125.66
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$169.00 K
|
$67.00 K
|
$201.00 K
|
| Net Income |
-$26.26 M
|
-$41.84 M
|
-$29.49 M
|
-$35.71 M
|
-$28.30 M
|
-$19.12 M
|
-$44.57 M
|
-$27.19 M
|
-$84.58 M
|
-$82.26 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-286.71
|
-125.97
|
| EPS |
-6.33 |
-1.5 |
-1.91 |
-3.18 |
-7.8 |
-612.56 |
-48.77 |
-263.65 |
-72406.33 |
-575.73 |
| EPS Diluted |
-6.33 |
-1.5 |
-1.91 |
-3.18 |
-7.8 |
-612.56 |
-48.77 |
-263.65 |
-72406.33 |
-575.73 |
| Weighted Average Shares Out |
$4.15 M
|
$27.90 M
|
$15.42 M
|
$888.00 K
|
$291.00 K
|
$31.21 K
|
$913.78 K
|
$103.14 K
|
$1.17 K
|
$142.88 K
|
| Weighted Average Shares Out Diluted |
$4.15 M
|
$27.90 M
|
$15.42 M
|
$888.38 K
|
$291.56 K
|
$31.21 K
|
$913.78 K
|
$103.14 K
|
$1.17 K
|
$142.88 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
